Biosergen

Flerie AB Acquires Biosergen AB: $54.7 M Merger Powers Antifungal Innovation and Capital Growth

Discover how Biosergen AB’s €54.7 M merger with Flerie AB will boost its antifungal pipeline, unlock new funding, and reshape biotech consolidation in Sweden.

Biosergen
Health Care
AI generated

28/06/2026, 01:03

2 minutes to read

Biogen AB Fuels Antifungal Growth: 54.7M SEK Valuation, 40M SEK Capital for BSG005

Biopharma breakthrough: Biosergen AB’s merger with Flerie and 40 M SEK funding boost accelerate BSG005 antifungal development, raising confidence and market reach.

Biosergen
Health Care
AI generated

26/06/2026, 17:43

2 minutes to read